Early Detection and Investigation of Extracellular Vesicles Biomarkers in Breast Cancer.
biomarkers
breast cancer
extracellular vesicles
liquid biopsy
plasma
Journal
Frontiers in molecular biosciences
ISSN: 2296-889X
Titre abrégé: Front Mol Biosci
Pays: Switzerland
ID NLM: 101653173
Informations de publication
Date de publication:
2021
2021
Historique:
received:
29
06
2021
accepted:
07
09
2021
entrez:
25
11
2021
pubmed:
26
11
2021
medline:
26
11
2021
Statut:
epublish
Résumé
Breast cancer (BC) is the most commonly diagnosed malignant tumor in women worldwide, and the leading cause of cancer death in the female population. The percentage of patients experiencing poor prognosis along with the risk of developing metastasis remains high, also affecting the resistance to current main therapies. Cancer progression and metastatic development are no longer due entirely to their intrinsic characteristics, but also regulated by signals derived from cells of the tumor microenvironment. Extracellular vesicles (EVs) packed with DNA, RNA, and proteins, are the most attractive targets for both diagnostic and therapeutic applications, and represent a decisive challenge as liquid biopsy-based markers. Here we performed a study based on a multiplexed phenotyping flow cytometric approach to characterize BC-derived EVs from BC patients and cell lines, through the detection of multiple antigens. Our data reveal the expression of EVs-related biomarkers derived from BC patient plasma and cell line supernatants, suggesting that EVs could be exploited for characterizing and monitoring disease progression.
Identifiants
pubmed: 34820420
doi: 10.3389/fmolb.2021.732900
pii: 732900
pmc: PMC8606536
doi:
Types de publication
Journal Article
Langues
eng
Pagination
732900Informations de copyright
Copyright © 2021 Bandini, Rossi, Scarpi, Gallerani, Vannini, Salvi, Azzali, Melloni, Salucci, Battistelli, Serra, Maltoni, Cho and Fabbri.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Oncol Lett. 2020 Nov;20(5):140
pubmed: 32934708
Int J Mol Sci. 2020 Dec 23;22(1):
pubmed: 33374539
Int J Mol Sci. 2020 Jul 30;21(15):
pubmed: 32751556
Biotechnol J. 2019 Jan;14(1):e1700716
pubmed: 29878510
World J Gastrointest Oncol. 2019 Nov 15;11(11):946-956
pubmed: 31798776
Cells. 2020 Jan 06;9(1):
pubmed: 31935901
Semin Cancer Biol. 2020 Feb;60:274-284
pubmed: 31491560
ACS Nano. 2020 Nov 24;14(11):14971-14988
pubmed: 32880442
J Cancer Res Clin Oncol. 2021 May;147(5):1431-1442
pubmed: 33760943
Front Cell Dev Biol. 2020 Oct 30;8:593750
pubmed: 33195266
Oncotarget. 2015 Apr 30;6(12):10253-66
pubmed: 25860935
J Extracell Vesicles. 2017 Feb 28;6(1):1294368
pubmed: 28326171
Front Genet. 2019 Mar 19;10:203
pubmed: 30941159
Ann Transl Med. 2019 Oct;7(20):593
pubmed: 31807574
Trends Cancer. 2020 Jun;6(6):489-505
pubmed: 32460003
Nat Rev Cancer. 2020 Dec;20(12):697-709
pubmed: 32958932
Nutrients. 2021 Mar 27;13(4):
pubmed: 33801634
Ann Oncol. 2019 May 1;30(5):781-787
pubmed: 30887043
Cancer Gene Ther. 2020 Jun;27(6):395-398
pubmed: 31477807
Bioconjug Chem. 2021 Jul 21;32(7):1306-1314
pubmed: 33475350
Open Biol. 2017 Dec;7(12):
pubmed: 29263247
Trends Cancer. 2021 Feb;7(2):122-133
pubmed: 33008796
Cancers (Basel). 2020 Sep 30;12(10):
pubmed: 33007968
Int J Clin Oncol. 2021 Aug;26(8):1431-1440
pubmed: 33835295
Med Chem. 2021;17(1):40-59
pubmed: 31808392
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
CA Cancer J Clin. 2006 Jan-Feb;56(1):37-47; quiz 50-1
pubmed: 16449185
Biomicrofluidics. 2019 Dec 05;13(6):064122
pubmed: 31832120
J Extracell Vesicles. 2019 Mar 12;8(1):1588538
pubmed: 30891164
J Hematol Oncol. 2018 May 10;11(1):64
pubmed: 29747682
Clin Transl Med. 2018 May 31;7(1):14
pubmed: 29855735
Cancer Manag Res. 2021 Jun 01;13:4417-4431
pubmed: 34103996
Cancers (Basel). 2017 Jun 24;9(7):
pubmed: 28672799
Cells. 2021 Jun 01;10(6):
pubmed: 34205944
J Extracell Vesicles. 2019 May 28;8(1):1615820
pubmed: 31191831
NPJ Breast Cancer. 2020 Oct 6;6:50
pubmed: 33083529
Cancer Lett. 2020 Oct 10;490:100-110
pubmed: 32659248
Signal Transduct Target Ther. 2020 Aug 11;5(1):148
pubmed: 32782280
Nat Commun. 2019 Dec 3;10(1):5499
pubmed: 31796750
Diagnostics (Basel). 2021 Mar 08;11(3):
pubmed: 33800141
Methods Mol Biol. 2015;1295:179-209
pubmed: 25820723
Int J Mol Sci. 2021 Jun 25;22(13):
pubmed: 34201940
Front Oncol. 2021 Aug 05;11:685009
pubmed: 34422639
Elife. 2021 Jan 06;10:
pubmed: 33404012
Proteomics. 2021 Jul;21(13-14):e2000094
pubmed: 33665903
J Extracell Vesicles. 2015 Jul 17;4:27031
pubmed: 26194179